The funding round was led by SFC Capital and OION to prepare the medical device startup for patient trials.
"A younger patient has about a 35% chance of implant failure during their lifetime, and the leading cause of failure is loss of fixation between the bone and the implant"
The Yorkshire-based medical technology company secured backing from Mercia and private investors to support production and international expansion.
"The Eventum team have done a massive amount of work in a short space of time in developing Quadsense and getting it approved for clinical use. We are now excited to start scaling up the team to commercialise the product, as well as bringing further innovations to the orthopaedics market."
QVentures led the pre-seed round with backing from Episode1 and industry angels to support the Meristem platform.
"Clinical trials are to medicine what elections are to democracy; they are the definitive process behind every significant step forwards and how we reason about what is effective and safe and what is not."
The funding round was backed by a group of existing investors alongside a grant from the European Innovation Council.
"This is a very significant funding milestone in our mission to detect cancer early and improve survival and quality of life for patients. Having demonstrated our multi-cancer capability, we can now focus on building the pipeline of organ-specific tests, beginning with a multi-center study to gain regulatory approval for the brain cancer test. We will also expand our data on colorectal cancer, one of the leading causes of death worldwide, and continue our work on collaborative projects."